Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lamotrigine

J A Messenheimer1

  • 1Department of Neurology, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill 27599-7025, USA.

Epilepsia
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Lamotrigine (LTG) is a new antiepileptic drug effective for partial seizures. It works by inhibiting glutamate release and blocking sodium channels, showing good tolerability in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final results from 18 years of the International Lamotrigine Pregnancy Registry.

Neurology·2011
Same author

Lamotrigine extended-release as adjunctive therapy for partial seizures.

Neurology·2007
Same author

Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures.

Neurology·2005
Same author

The tolerability of lamotrigine in children.

Drug safety·2000
Same author

Rash with lamotrigine: dosing guidelines.

Epilepsia·2000
Same author

Rash in adult and pediatric patients treated with lamotrigine.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·1998
Same journal

Factors associated with rapid pediatric acute seizure emergency treatment: Quality Improvement in Time to Treat Status Epilepticus baseline cohort.

Epilepsia·2026
Same journal

Outcome trajectories after pediatric epilepsy surgery vary by biopsychosocial phenotypes.

Epilepsia·2026
Same journal

Comparative risk of epilepsy with SGLT2 inhibitors versus incretin-based therapies in type 2 diabetes.

Epilepsia·2026
Same journal

Long-term mortality after status epilepticus: A 5-year analysis study.

Epilepsia·2026
Same journal

The Epilepsy-Cog study: Methods to establish a harmonized study of late onset epilepsy in a metacohort of six population-based cohorts in the United States.

Epilepsia·2026
Same journal

Systematic review and meta-analysis of lifestyle modification interventions and their impact on seizure reduction and quality of life.

Epilepsia·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Neurology

Background:

  • Lamotrigine (LTG) is an antiepileptic drug (AED) with demonstrated efficacy in animal models.
  • Its activity spectrum is comparable to phenytoin and carbamazepine, with potential for broader application and improved tolerability.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of lamotrigine as an add-on therapy for medically refractory partial seizures.
  • To elucidate the mechanism of action of lamotrigine, focusing on neurotransmitter release and ion channel activity.

Main Methods:

  • Clinical trials involving patients with medically refractory partial seizures receiving lamotrigine as add-on therapy.
  • In vitro studies investigating the effects of lamotrigine on excitatory neurotransmitter release and voltage-sensitive sodium channels.

Related Experiment Videos

Main Results:

  • Lamotrigine consistently achieved a 50% reduction in seizure frequency in 25-34% of subjects.
  • The drug demonstrated good tolerability, with positive behavioral effects noted.
  • Key pharmacologic properties include low protein binding, absence of enzyme induction, and linear pharmacokinetics.
  • The primary adverse effect was rash, leading to a 2% withdrawal rate.

Conclusions:

  • Lamotrigine is an effective and well-tolerated add-on treatment for partial seizures.
  • Its mechanism involves inhibiting glutamate release via voltage-sensitive sodium channel blockade.
  • Favorable pharmacokinetic properties and a manageable side effect profile support its clinical utility.